Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
FOLD

FOLD - Amicus Therapeutics Inc Stock Price, Fair Value and News

$10.02-0.20 (-1.96%)
Market Closed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

FOLD RSI Chart

2024AprJulOct20406080

FOLD Valuation

Market Cap

3.0B

Price/Earnings (Trailing)

-25.36

Price/Sales (Trailing)

6.65

EV/EBITDA

-77.38

Price/Free Cashflow

-63.02

FOLD Price/Sales (Trailing)

2022202320246789101112

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

FOLD Fundamentals

FOLD Revenue

Revenue (TTM)

455.7M

Rev. Growth (Yr)

34.04%

Rev. Growth (Qtr)

14.73%

201020122014201620182020202220240100M200M300M400M500M

FOLD Earnings

Earnings (TTM)

-119.5M

Earnings Growth (Yr)

63.69%

Earnings Growth (Qtr)

67.58%

2005201020152020-400M-300M-200M-100M0

FOLD Price Action

Last 7 days

-4.5%

Last 30 days

-12.4%

Last 90 days

-1.1%

Trailing 12 Months

-7.9%

FOLD Profitability

Operating Margin

97.40%

EBT Margin

-21.91%

Return on Equity

-90.2%

Return on Assets

-15.95%

Free Cashflow Yield

-1.59%

FOLD Financial Health

Current Ratio

2.75

Debt/Equity

2.93

Debt/Cashflow

-0.11

FOLD Investor Care

Shares Dilution (1Y)

3.30%

Diluted EPS (TTM)

-0.39

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
201020122014201620182020202220240100M200M300M400M500M
Net sales
YearQ1Q2Q3Q4
2024423.5M455.7M00
2023336.8M350.6M372.4M399.4M
2022317.8M321.1M323.3M329.2M
2021266.8M281.8M293.9M305.5M
2020208.7M226.9M245.6M260.9M
2019108.6M131.4M159.6M182.2M
201849.5M63.6M73.3M91.2M
20179.1M16.3M25.0M36.9M
2016002.9M5.3M
201411.5M8.1M4.7M1.2M
201300015.0M
201223.2M29.8M24.0M18.4M
201147.2M38.6M30.0M21.4M
201000055.8M
200900064.4M
FOLD
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. The company also develops AT-GAA, a novel treatment paradigm for Pompe disease; and enzyme replacement therapies for Pompe diseases. It has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. The company was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
 CEO
 WEBSITEhttps://amicusrx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES484

Amicus Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Amicus Therapeutics Inc? What does FOLD stand for in stocks?

FOLD is the stock ticker symbol of Amicus Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Amicus Therapeutics Inc (FOLD)?

As of Mon Oct 07 2024, market cap of Amicus Therapeutics Inc is 3.03 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of FOLD stock?

You can check FOLD's fair value in chart for subscribers.

Is Amicus Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether FOLD is over valued or under valued. Whether Amicus Therapeutics Inc is cheap or expensive depends on the assumptions which impact Amicus Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for FOLD.

What is Amicus Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Oct 07 2024, FOLD's PE ratio (Price to Earnings) is -25.36 and Price to Sales (PS) ratio is 6.65. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. FOLD PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Amicus Therapeutics Inc's stock?

In the past 10 years, Amicus Therapeutics Inc has provided 0.051 (multiply by 100 for percentage) rate of return.